Clinical trial

Peritransplant Deoxyspergualin in Islet Transplantation in Type 1 Diabetes

NCT00434850

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2006-10-01

PhasePHASE2

Study timeline

Study start (unknown)2006-10-01Date precision: month

Registry last updated2016-03-16

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Diabetes Mellitus, Type 1unresolved

Interventions

Allogeneic Pancreatic Islet CellsBIOLOGICAL

DeoxyspergualinDRUG

Antithymocyte globulinBIOLOGICAL

Daclizumab or basiliximabBIOLOGICAL

SirolimusDRUG · verified · RxNorm: sirolimus

TacrolimusDRUG · verified · RxNorm: tacrolimus

EtanerceptBIOLOGICAL

Sponsors & collaborators

National Institute of Allergy and Infectious Diseases (NIAID)lead sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)collaborator

Mapped research locations

ChicagoIllinois, United States1 San FranciscoCalifornia, United States1 MinneapolisMinnesota, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00434850 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.